{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:48:09Z","timestamp":1791042489751,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.jhep.2009.10.004","type":"journal-article","created":{"date-parts":[[2009,10,22]],"date-time":"2009-10-22T12:46:04Z","timestamp":1256215564000},"page":"106-111","source":"Crossref","is-referenced-by-count":50,"title":["Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis"],"prefix":"10.1016","volume":"52","author":[{"given":"Ulf","family":"Hindorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khatoon","family":"Jahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Verbaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Prytz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Wallerstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e5rten","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Bj\u00f6rnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curt","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven H.C.","family":"Almer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2009.10.004_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/oxfordjournals.qjmed.a067264","article-title":"Controlled prospective trial of corticosteroid therapy in active chronic hepatitis","volume":"40","author":"Cook","year":"1971","journal-title":"QJM"},{"key":"10.1016\/j.jhep.2009.10.004_bib2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2009.10.004_bib3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"1","author":"Murray-Lyon","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2009.10.004_bib4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/hep.1840080414","article-title":"Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal","volume":"8","author":"Stellon","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.10.004_bib5","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJM199510123331502","article-title":"Azathioprine for long-term maintenance of remission in autoimmune hepatitis","volume":"333","author":"Johnson","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2009.10.004_bib6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1399-3046.2004.00230.x","article-title":"Utility of azathioprine metabolite measurements in post-transplant recurrent autoimmune and immune-mediated hepatitis","volume":"8","author":"Rumbo","year":"2004","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jhep.2009.10.004_bib7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00007691-199608000-00003","article-title":"Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase polymorphism","volume":"18","author":"Lennard","year":"1996","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jhep.2009.10.004_bib8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0026-895X(24)12548-5","article-title":"Human RNase H-mediated RNA cleavage from DNA\u2013RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA","volume":"56","author":"Krynetskaia","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jhep.2009.10.004_bib9","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2009.10.004_bib10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/00007691-200412000-00014","article-title":"Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy. Results from a large Swedish patient population","volume":"26","author":"Hindorf","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jhep.2009.10.004_bib11","first-page":"5810","article-title":"Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells","volume":"61","author":"Derviuex","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2009.10.004_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00008571-200404000-00006","article-title":"Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity","volume":"14","author":"Lindqvist","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jhep.2009.10.004_bib13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/01.fpc.0000114745.08559.db","article-title":"Comprehensive analysis of thiopurine S-methyltransferase phenotype\u2013genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants","volume":"14","author":"Schaeffeler","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jhep.2009.10.004_bib14","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/humu.9450","article-title":"Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22)\u2014association with decreased enzyme function","volume":"27","author":"Schaeffeler","year":"2006","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jhep.2009.10.004_bib15","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/FPC.0b013e3282ef642b","article-title":"Explaining TPMT genotype\/phenotype discrepancy by haplotyping of TPMT*3A and identification of a novel sequence variant, TPMT*23","volume":"17","author":"Lindqvist","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jhep.2009.10.004_bib16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bcp.2008.05.009","article-title":"Characterisation of novel defective thiopurine S-methyltransferase allelic variants","volume":"76","author":"Garat","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhep.2009.10.004_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/clpt.1989.119","article-title":"Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism","volume":"46","author":"Lennard","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2009.10.004_bib18","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/gut.48.5.642","article-title":"Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease","volume":"48","author":"Cuffari","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2009.10.004_bib19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1046\/j.1365-2036.2003.01683.x","article-title":"Thioguanine in patients with Crohn\u2019s disease intolerant or resistant to azathioprine\/mercaptopurine","volume":"18","author":"Bonaz","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2009.10.004_bib20","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/00365520410007980","article-title":"Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease","volume":"39","author":"Hindorf","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2009.10.004_bib21","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/gast.2002.32420","article-title":"6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease","volume":"122","author":"Dubinsky","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2009.10.004_bib22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0168-8278(02)00214-3","article-title":"Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis","volume":"37","author":"Langley","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2009.10.004_bib23","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2006.05.011","article-title":"Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis","volume":"45","author":"Heneghan","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2009.10.004_bib24","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s10620-006-9336-5","article-title":"Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis","volume":"51","author":"Czaja","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2009.10.004_bib25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00005176-200209000-00032","article-title":"Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report","volume":"35","author":"Rumbo","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2009.10.004_bib26","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2009.10.004_bib27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ejim.2008.12.011","article-title":"Transitions between variant forms of primary biliary cirrhosis during long-term follow-up","volume":"20","author":"Lindgren","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhep.2009.10.004_bib28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejim.2008.06.004","article-title":"High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis","volume":"20","author":"Olsson","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhep.2009.10.004_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00007691-200206000-00005","article-title":"Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate","volume":"24","author":"Pettersson","year":"2002","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jhep.2009.10.004_bib30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1373\/clinchem.2003.023846","article-title":"Pyrosequencing of TPMT alleles in a general Swedish population and in patients with inflammatory bowel disease","volume":"50","author":"Haglund","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.jhep.2009.10.004_bib31","first-page":"423","article-title":"A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate","volume":"91","author":"Sandborn","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2009.10.004_bib32","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1053\/j.gastro.2006.01.046","article-title":"Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis","volume":"130","author":"Osterman","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2009.10.004_bib33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/14656566.7.2.145","article-title":"Cost-effectiveness of pharmacotherapy for autoimmune hepatitis","volume":"7","author":"Heneghan","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jhep.2009.10.004_bib34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2036.2005.02583.x","article-title":"Allopurinol safely and effectively optimizes thioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine","volume":"22","author":"Sparrow","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2009.10.004_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cgh.2006.11.020","article-title":"Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine","volume":"5","author":"Sparrow","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2009.10.004_bib36","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2036.2008.03925.x","article-title":"Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease","volume":"29","author":"Hindorf","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2009.10.004_bib37","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1053\/j.gastro.2006.01.047","article-title":"American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease","volume":"130","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2009.10.004_bib38","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/01.fpc.0000236322.88433.ac","article-title":"Adding pharmacogenetics information to drug labels: lessons learned","volume":"16","author":"Haga","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jhep.2009.10.004_bib39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2036.2006.02977.x","article-title":"Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease","volume":"24","author":"Hindorf","year":"2006","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827809006503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827809006503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T21:57:46Z","timestamp":1739397466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827809006503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0168827809006503"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2009.10.004","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}